Immediate results of using a frame-mounted xeno-pericardial bioprosthesis in mitral position with an Easy Change System

Abstract

Aim. To assess the immediate results of mitral valve prosthetics with the MedEng-BIO biological valve based on 19 clinical observations.
Material and Methods. The implantation of the MedEng-BIO biological valve prosthesis to the mitral position was performed in 19 patients at the Cardiology Research Institute of Tomsk National Research Medical Center of the Russian Academy of Science (Tomsk, Russia) between February 2017 and January 2019. The average age of patients was 68.7 ± 5.4 years. The NYHA functional class was 2.61 ± 0.50. The average peak preoperative gradient was 18.3 ± 5.9 mmHg; the mean gradient was 7.1 ± 3.3 mmHg. All the patients underwent echocardiography to study the mitral valve, the left ventricular function, the left atrial (LA) size, and the right ventricular systolic pressure (RVSP) preoperatively and before the discharge (14 days after the surgery on average).
Results. There were no statistically significant changes in the left ventricular function; the decreases in the LA sizes and the RVSP are shown in Table 2. The effective opening areas of the MedEng-BIO valves of the sizes 27, 29, and 31 were 3.2, 2.7, and 2.06 cm2, respectively.
Conclusions. The first experience of using the MedEng-BIO biological mitral valve prostheses demonstrated satisfactory clinical outcomes with the simplification of the implantation procedure and a possible decrease in the risk of postoperative complications in repeated interventions. However, more cases and more extended observations are needed to draw final and statistically significant conclusions on the effect and feasibility of this surgical procedure.